Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.71 |
| ▸ | ABL1 | P00519 | 10/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13673230 | 0.89 | PIK3CD (0.81) | PIK3CDPIK3CGPIK3CAABL1 | |
| SCHEMBL12565515 | 0.88 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CAABL1 | |
| SCHEMBL13673276 | 0.88 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CAABL1 | |
| SCHEMBL12565508 | 0.87 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3CAABL1 | |
| SCHEMBL12565506 | 0.86 | PIK3CD (0.76) | PIK3CDPIK3CGPIK3CAABL1NPC1 | |
| SCHEMBL1946980 | 0.86 | PIK3CD (0.76) | PIK3CDPIK3CGPIK3CAABL1 | |
| SCHEMBL12565510 | 0.86 | PIK3CD (0.75) | PIK3CDPIK3CGPIK3CAABL1 | |
| SCHEMBL12565512 | 0.86 | PIK3CD (0.75) | PIK3CDPIK3CGPIK3CAABL1NPC1 | |
| SCHEMBL12543310 | 0.85 | PIK3CG (0.76) | PIK3CDPIK3CGPIK3CAABL1NPC1 | |
| SCHEMBL3710994 | 0.85 | PIK3CD (0.74) | PIK3CDPIK3CGPIK3CAABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110135603-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110135603-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2009129211-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135603-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CG, PIK3CD | PIK3CD 3/4885PIK3CG 2/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.